Fig. 1From: Payload diversification: a key step in the development of antibody–drug conjugatesFDA approval of anticancer ADCs. ADCs are identified according to the nature of their payload: Microtubule-disrupting agents; DNA-targeting agents: Calicheamicin, pyrrolobenzodiazepine (PBD), topoisomerase 1 (TOPO 1) inhibitorBack to article page